Keller F, Kunzendorf U, Walz G, Haller H, Offermann G
Freie Universität, Klinikum Steglitz, Abteilung für Allgemeine, Berlin, West Germany.
J Clin Pharmacol. 1989 Mar;29(3):240-5. doi: 10.1002/j.1552-4604.1989.tb03320.x.
Reduced bioavailability (F) due to hepatic first-pass extraction of an oral dose (D) is a well-known pharmacokinetic phenomenon. An integrated solution for Michaelis-Menten kinetics of the first-pass effect is derived from the maximal metabolic rate (Vm), volume of distribution (Vd), first order absorption rate constant (ka), Michaelis constant (Km), and liver blood flow (Q). F = 1 - VmVd/kaD ln (1 + kaD/QKm) This equation for single dosage can also be extended to steady state kinetics after multiple dosing in which the amount of a drug present in the hepatic circulation is considered. According to the literature, the bioavailability of a single 80 mg oral dose of propranolol (F = 0.22) increases after multiple doses Fss = 0.36). Based on the first pass equations for single dosage and multiple dosing, the maximal metabolic rate (Vm = 0.043 mg l-1 h-1) corresponding to 310 mg per day and the Michaelis constant (Km = 0.10 mg/l) were calculated for propranolol. Incorporation of nonlinear plasma protein binding in this concept may explain the lack of threshold phenomenon for a single dose of less than 40 mg propranolol. Zero order absorption kinetics could explain why cumulation kinetics seem linear even at an excessive dosage of 960 mg propranolol per day. From these derivations it may be concluded that multiple dosing, increase in plasma protein binding, high absorption rate, and increased portal venous blood flow will increase bioavailability, whereas slow release formulations, fractional drug dosage, and saturable absorption kinetics will decrease bioavailability of first-pass drugs like propranolol.
口服剂量(D)因肝脏首过消除导致生物利用度(F)降低是一种众所周知的药代动力学现象。首过效应的米氏动力学综合解决方案源自最大代谢率(Vm)、分布容积(Vd)、一级吸收速率常数(ka)、米氏常数(Km)和肝血流量(Q)。F = 1 - VmVd/kaD ln (1 + kaD/QKm) 该单剂量方程也可扩展到多次给药后的稳态动力学,其中考虑了肝循环中存在的药物量。根据文献,单次口服80 mg普萘洛尔的生物利用度(F = 0.22)在多次给药后会增加(Fss = 0.36)。基于单剂量和多剂量的首过方程,计算出普萘洛尔的最大代谢率(Vm = 0.043 mg l-1 h-1,相当于每天310 mg)和米氏常数(Km = 0.10 mg/l)。在这一概念中纳入非线性血浆蛋白结合可能解释了单次剂量小于40 mg普萘洛尔时缺乏阈值现象的原因。零级吸收动力学可以解释为什么即使在每天960 mg普萘洛尔的过量剂量下,累积动力学似乎也是线性的。从这些推导可以得出结论,多次给药、血浆蛋白结合增加、高吸收速率和门静脉血流量增加会提高生物利用度,而缓释制剂、分次给药剂量和饱和吸收动力学将降低普萘洛尔等首过药物的生物利用度。